<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154828">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02059291</url>
  </required_header>
  <id_info>
    <org_study_id>CACZ885N2301</org_study_id>
    <nct_id>NCT02059291</nct_id>
  </id_info>
  <brief_title>Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers</brief_title>
  <official_title>Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Denmark: Danish Medicines Agency</authority>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <authority>Russia: Pharmacological Committee, Ministry of Health</authority>
    <authority>Switzerland: Swissmedic</authority>
    <authority>Turkey: Ministry of Health</authority>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Finland: Finnish Medicines Agency</authority>
    <authority>France: L'Agence nationale de sécurité du médicament et des produits de santé (ANSM)</authority>
    <authority>Greece: National Organization of Medicines</authority>
    <authority>Hungary: National Institute of Pharmacy</authority>
    <authority>Ireland: Irish Medicines Board</authority>
    <authority>Israel: Ministry of Health</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <authority>Netherlands: Dutch Health Care Inspectorate</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      ThIS study is to determine whether canakinumab is able to induce and maintain a clinically
      meaningful reduction of disease activity in participants with HPF (Hereditary Periodic
      Fevers) compared to placebo.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Proportion of participants with resolution of initial flare at time of the randomization and absence of new flares</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To demonstrate significant reduction of disease activity with canakinumab versus placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who achieve Physician's global assessment &lt; 2</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessment of Physician's global assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participantswith the serologic remission</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Normalization of C-reactive protein, Serum Amyloid A</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Hereditary Periodic Fevers</condition>
  <arm_group>
    <arm_group_label>canakinumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>canakinumab</intervention_name>
    <description>subcutaneous injection</description>
    <arm_group_label>canakinumab</arm_group_label>
    <other_name>ACZ885</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>subcutaneous injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: - Patient's written informed consent (or parent's written informed
        consent in case of pediatric patient) at screening - Male and female patients at least 2
        years of age at the time of the screening visit. - Confirmed diagnosis and active flare at
        randomization - CRP &gt;10mg/L at randomization

        Exclusion Criteria: - Use of the following therapies (within varying protocol defined
        timeframes): Corticosteroids, anakinra, canakinumab, rilonacept, tocilizumab, TNF
        inhibitors, abatacept, tofacitinib, rituximab, leflunomide, thalidomide, cyclosporine,
        intravenous immunoglobulin, 6-Merceptopurine, azathioprine, cyclophosphamide, or
        chlorambucil, any other investigational biologics - History of malignancy of any organ
        system (other than localized basal cell carcinoma of the skin or in - situ cervical
        cancer), treated or untreated - Significant medical diseases, including but not limited to
        the following: a. History of organ transplantation b. Elevated liver enzymes ≥2x ULN d.
        Increase in total bilirubin e. Serious hepatic disorder (Child-Pugh scores B or C) f.
        Chronic Kidney Disease g. Thyroid disease h. Diagnosis of active peptic ulcer disease i.
        Coagulopathy j. Significant CNS effects including vertigo and dizziness - Any conditions
        or significant medical problems which immunecompromise the patient and/or places the
        patient at unacceptable risk for immunomodulatory therapy - Live vaccinations within 3
        months prior to the start of the trial, during the trial, and up to 3 months following the
        last dose
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 20, 2014</lastchanged_date>
  <firstreceived_date>February 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Canakinumab, interleukin-1, Hereditary Periodic Fevers, auto-inflammatory diseases</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fever</mesh_term>
    <mesh_term>Familial Mediterranean Fever</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
    <mesh_term>Hereditary Autoinflammatory Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
